ASLAN003 is a small molecule inhibitor of DiHydroOrotate DeHydrogenase (DHODH), an enzyme which catalyses the key rate-limiting step in the synthesis of pyrimidines in mammalian cells (Company Pipeline, ASLAN Pharmaceuticals, MAY 31, 2016, View Source [SID:1234512877]). In studies conducted to date, ASLAN003 has generated promising emerging preclinical data in oncology indications where the mechanism is linked with induction of p53 and apoptosis. ASLAN plans to develop ASLAN003 in several oncology indications as monotherapy and in combination with other targeted agents.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!